How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

13,039 results for

Diabetes Mellitus Control in Hospital

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. In-hospital, short-term and long-term adverse clinical outcomes observed in patients with type 2 diabetes mellitus vs non-diabetes mellitus following percutaneous coronary intervention: A meta-analysis including 139,774 patients. (PubMed)

manifested.According to this meta-analysis including a total number of 139,774 patients, following PCI, those patients with T2DM suffered more in-hospital, short as well as long-term adverse outcomes as reported by most of the Randomized Controlled Trials and Observational studies, compared to those patients without diabetes mellitus. (...) In-hospital, short-term and long-term adverse clinical outcomes observed in patients with type 2 diabetes mellitus vs non-diabetes mellitus following percutaneous coronary intervention: A meta-analysis including 139,774 patients. Several studies have shown that patients with type 2 diabetes mellitus (T2DM) have worse clinical outcomes in comparison to patients without diabetes mellitus (DM) following Percutaneous Coronary Intervention (PCI). However, the adverse clinical outcomes were

2019 Medicine

2. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians

Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians ACP Guidance Statement on HbA | Annals of Internal Medicine | American College of Physicians '); } Sign in below to access your subscription for full content INDIVIDUAL SIGN IN | You will be directed to acponline.org to register and create your Annals account INSTITUTIONAL SIGN IN | | Subscribe to Annals (...) of Internal Medicine . You will be directed to acponline.org to complete your purchase. Search Clinical Guidelines | 17 April 2018 Hemoglobin A 1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians Free Amir Qaseem, MD, PhD, MHA; Timothy J. Wilt, MD, MPH; Devan Kansagara, MD, MCR; Carrie Horwitch, MD, MPH; Michael J. Barry, MD; Mary Ann Forciea, MD; for the Clinical Guidelines

Full Text available with Trip Pro

2018 American College of Physicians

3. Basal–Bolus Insulin Therapy with Gla-300 During Hospitalization Reduces Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study (PubMed)

Basal–Bolus Insulin Therapy with Gla-300 During Hospitalization Reduces Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study Although reduction in the incidence of nocturnal hypoglycemia, as estimated by symptom or self-monitored plasma glucose, was shown to be more pronounced with 300 units/mL insulin glargine (Gla-300) than with 100 units/mL insulin glargine (Gla-100) in type 2 diabetes patients, the exact frequency of nocturnal hypoglycemia (...) estimated with continuous glucose monitoring (CGM) has not been reported.Forty patients with type 2 diabetes who were admitted for glycemic control with basal-bolus insulin therapy (BBT) were randomized into the Gla-100 and Gla-300 groups. Insulin doses were adjusted to maintain blood glucose levels within 100-120 mg/dL at each meal. Plasma glucose and C-peptide profiles were estimated serially after admission and before discharge. Daily CGM was also performed before discharge.In the Gla-100 and Gla-300

Full Text available with Trip Pro

2018 Diabetes Therapy

4. Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

therapy AE adverse event G-BA Gemeinsamer Bundesausschuss (Federal Joint Committee) IQWiG Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care) RCT randomized controlled trial SAE serious adverse event SGB Sozialgesetzbuch (Social Code Book) SPC Summary of Product Characteristics HbA1c haemoglobin A1c Extract of dossier assessment A17-66 Version 1.0 Dapagliflozin/metformin (type 2 diabetes mellitus) 28 March 2018 Institute for Quality (...) ) in the following approved therapeutic indication: ? as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximally tolerated dose of metformin alone. The assessment was conducted in comparison with the G-BA’s ACT. This ACT is shown in Table 2. Table 2: Research question of the benefit assessment of dapagliflozin/metformin in type 2 diabetes mellitus Subindication ACT a Dapagliflozin/metformin ? Metformin + sulfonylurea (glibenclamide or glimepiride) b

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

5. Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

of adult patients with type 2 diabetes mellitus in comparison with the appropriate comparator therapy (ACT) in the following approved therapeutic indication: ? Dapagliflozin in combination with metformin (dapagliflozin + metformin): in patients in whom monotherapy with metformin together with diet and exercise does not provide adequate glycaemic control. The assessment was conducted in comparison with the G-BA’s ACT. This ACT is shown in Table 2. Table 2: Research question of the benefit assessment (...) DapaZu study The DapaZu study is a randomized, active-controlled, double-blind phase 4 study. Adult patients between 18 and 74 years with type 2 diabetes mellitus in whom no sufficient glycaemic control was achieved despite treatment with metformin at a stable maximum tolerated dosage of = 1500 mg/day and who had a glycosylated haemoglobin A1c (HbA1c) value between = 7.5% and = 10.5% in the inclusion phase were included in the study. The study consisted of a 2-week inclusion phase, a treatment phase

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

6. Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2

Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2 Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2 - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2 The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our

2017 Clinical Trials

7. Socioeconomic Deprivation, Household Education, and Employment are Associated With Increased Hospital Admissions and Poor Glycemic Control in Children With Type 1 Diabetes Mellitus (PubMed)

Socioeconomic Deprivation, Household Education, and Employment are Associated With Increased Hospital Admissions and Poor Glycemic Control in Children With Type 1 Diabetes Mellitus Socioeconomic deprivation, obesity, and emotional discomfort are important determinants of health inequalities and poor glycemic control in children and young people with type 1 diabetes mellitus (T1D).The aims of this study were to evaluate the incidence of hospital admissions of T1D children in relation (...) = 0.07) and overall deprivation (r = -0.17, p = 0.06). Glycemic control was not found to be associated with BMI, standard deviation scores (SDS), or emotional well-being.Early intervention and education from primary care and specialist diabetes teams within the community in deprived areas may be effective in reducing hospital admissions for diabetes-related problems and improving glycemic control.

Full Text available with Trip Pro

2017 The review of diabetic studies : RDS

8. Role of glycemic control on hospital-related outcomes in patients with diabetes mellitus undergoing renal transplantation (PubMed)

Role of glycemic control on hospital-related outcomes in patients with diabetes mellitus undergoing renal transplantation To compare length of stay (LOS) and incidence of hypoglycemic events and infections in hospitalized patients with diabetes mellitus (DM) undergoing renal transplantation, among groups of patients defined by admission glucose and mean inpatient daily glucose.A retrospective analysis of 190 charts of patients with DM who underwent renal transplantation over a 2-year period (...) in diabetes patients undergoing renal transplantation. Our findings suggest that target blood glucose levels of 140-180 mg/dL may be appropriate in this specific population. Additional prospective research is needed to confirm these findings.

Full Text available with Trip Pro

2017 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

9. A comparative study of the quality of care and glycemic control among ambulatory type 2 diabetes mellitus clients, at a Tertiary Referral Hospital and a Regional Hospital in Central Kenya (PubMed)

A comparative study of the quality of care and glycemic control among ambulatory type 2 diabetes mellitus clients, at a Tertiary Referral Hospital and a Regional Hospital in Central Kenya Peripheral public health facilities remain the most frequented by the majority of the population in Kenya; yet remain sub-optimally equipped and not optimized for non-communicable diseases care.We undertook a descriptive, cross sectional study among ambulatory type 2 diabetes mellitus clients, attending (...) intervals; incurred half to three quarter lower direct costs, and reported greater affordability and satisfactions with care.In conclusion, we demonstrate that in Thika district hospital, glycemic control and diabetic care is suboptimal; but comparable to that of Kenyatta National Referral hospital. Opportunities for improvement of care abound at peripheral health facilities.

Full Text available with Trip Pro

2016 BMC research notes

10. Adherence to antidiabetic medication and factors associated with non-adherence among patients with type-2 diabetes mellitus in two regional hospitals in Cameroon. (PubMed)

Adherence to antidiabetic medication and factors associated with non-adherence among patients with type-2 diabetes mellitus in two regional hospitals in Cameroon. Diabetes mellitus is a growing cause of disease burden globally. Its management is multifaceted, and adherence to pharmacotherapy is known to play a significant role in glycaemic control. Data on medication adherence among affected patients is unknown in Cameroon. In this study, the level of adherence and factors influencing non (...) -adherence to antidiabetic medication among patients with type-2 diabetes was assessed.A hospital-based cross-sectional study among adult patients receiving care in the diabetic clinics of the Limbe and Bamenda Regional Hospitals in Cameroon was conducted. Medication adherence was assessed using the Medication Compliance Questionnaire (MCQ). Factors associated with non-adherence to medication were determined using basic and adjusted multivariable logistic regression models.A total of 195 patients

Full Text available with Trip Pro

2019 BMC Endocrine Disorders

11. Sliding scale insulin for non-critically ill hospitalised adults with diabetes mellitus. (PubMed)

effects.We are uncertain which insulin strategy (SSI or basal-bolus insulin) is best for non-critically hospitalised adults with diabetes mellitus. A basal-bolus insulin strategy in these patients might result in better short-term glycaemic control but could increase the risk for severe hypoglycaemic episodes. The certainty of the body of evidence comparing SSI with basal-bolus insulin was low to very low and needs to be improved by adequately performed, well-powered RCTs in different hospital (...) Sliding scale insulin for non-critically ill hospitalised adults with diabetes mellitus. Diabetes mellitus is a metabolic disorder resulting from a defect in insulin secretion, function, or both. Hyperglycaemia in non-critically ill hospitalised people is associated with poor clinical outcomes (infections, prolonged hospital stay, poor wound healing, higher morbidity and mortality). In the hospital setting people diagnosed with diabetes receive insulin therapy as part of their treatment

2018 Cochrane

12. Response to Comment on Koivusalo et al. Gestational Diabetes Mellitus Can Be Prevented by Lifestyle Intervention: The Finnish Gestational Diabetes Prevention Study (RADIEL): A Randomized Controlled Trial. Diabetes Care 2016;39:24-30. (PubMed)

Response to Comment on Koivusalo et al. Gestational Diabetes Mellitus Can Be Prevented by Lifestyle Intervention: The Finnish Gestational Diabetes Prevention Study (RADIEL): A Randomized Controlled Trial. Diabetes Care 2016;39:24-30. 27457642 2018 01 05 2018 12 02 1935-5548 39 8 2016 08 Diabetes care Diabetes Care Response to Comment on Koivusalo et al. Gestational Diabetes Mellitus Can Be Prevented by Lifestyle Intervention: The Finnish Gestational Diabetes Prevention Study (RADIEL (...) ): A Randomized Controlled Trial. Diabetes Care 2016;39:24-30. e126-7 10.2337/dci16-0014 Koivusalo Saila Birgitta SB Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Jorvi Hospital, Espoo, Finland saila.koivusalo@helsinki.fi. Rönö Kristiina K Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Women's Hospital, Helsinki, Finland. Stach-Lempinen Beata B 0000-0002-6344-1159 Department of Obstetrics and Gynaecology

Full Text available with Trip Pro

2018 Diabetes Care

13. Effect of oral vitamin D supplementation on glycemic control in patients with type 2 diabetes mellitus with coexisting hypovitaminosis D: A parellel group placebo controlled randomized controlled pilot study. (PubMed)

and coexisting hypovitaminosis D.Randomized, Parallel Group, Placebo Controlled Trial carried out in a tertiary care hospital of Indian Armed Forces.Sixty patients with coexisting type 2 diabetes mellitus and hypovitaminosis D were randomized into cases and controls and were supplemented with oral Vitamin D and microcrystalline cellulose respectively for six months. Subjects' HbA1c and vitamin D levels were monitored at the beginning and end of the study, fasting plasma glucose (FPG) & post prandial plasma (...) Effect of oral vitamin D supplementation on glycemic control in patients with type 2 diabetes mellitus with coexisting hypovitaminosis D: A parellel group placebo controlled randomized controlled pilot study. Vitamin D supplementation in type 2 diabetes mellitus patients may lead to improved glycemic control by improving insulin secretion and decreasing insulin resistance.To investigate effect of oral vitamin D supplementation on glycemic control, in patients with type 2 diabetes mellitus

2018 Diabetes & metabolic syndrome

14. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. (PubMed)

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. Previous trial results have suggested that dipeptidyl peptidase 4 inhibitor (DPP4i) use might increase heart failure (HF) risk in type 2 diabetes mellitus (T2DM). The DPP4i sitagliptin has been shown to be noninferior to placebo with regard to primary and secondary composite atherosclerotic cardiovascular (CV) outcomes (...) in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS).To assess the association of sitagliptin use with hospitalization for HF (hHF) and related outcomes.TECOS was a randomized, double-blind, placebo-controlled study evaluating the CV safety of sitagliptin vs placebo, each added to usual antihyperglycemic therapy and CV care among patients with T2DM and prevalent atherosclerotic vascular disease. The median follow-up was 2.9 years. The setting was 673 sites in 38 countries. Participants

Full Text available with Trip Pro

2016 JAMA cardiology

15. Management of hospitalized type 2 diabetes mellitus patients (PubMed)

Management of hospitalized type 2 diabetes mellitus patients Both hyperglycemia and hypoglycemia in hospitalized patients are associated with adverse outcomes including increased rates of infection, longer hospital length of stay, and even death. Clinical trials in patients with type 2 diabetes mellitus proved that by improving glycemic control, we can reduce all of them. Insulin is the preferred treatment for glycemic control in most cases, but alternative treatment options that can normalize (...) blood glucose levels without hypoglycemia are being sought. Moreover, hospitalized patients are particularly vulnerable to severe, prolonged hypoglycemia since they may be unable to sense or respond to the early warning signs and symptoms of low blood glucose. Finally, nutritional support, corticosteroid therapy, and surgery increase the risk of hyperglycemia that leads to an increased risk of morbidity and mortality. We review the management of type 2 diabetes mellitus patients who are admitted

Full Text available with Trip Pro

2016 Journal of translational internal medicine

16. Gender, alexithymia and physical inactivity associated with abdominal obesity in type 1 diabetes mellitus: a cross sectional study at a secondary care hospital diabetes clinic (PubMed)

Gender, alexithymia and physical inactivity associated with abdominal obesity in type 1 diabetes mellitus: a cross sectional study at a secondary care hospital diabetes clinic Obesity is linked to cardiovascular diseases and increasingly common in type 1 diabetes mellitus (T1DM) since the introduction of intensified insulin therapy. Our main aim was to explore associations between obesity and depression, anxiety, alexithymia and self-image measures and to control for lifestyle variables (...) in a sample of persons with T1DM. Secondary aims were to explore associations between abdominal and general obesity and cardiovascular complications in T1DM.Cross sectional study of 284 persons with T1DM (age 18-59 years, men 56%), consecutively recruited from one secondary care hospital diabetes clinic in Sweden. Assessments were performed with self-report instruments (Hospital Anxiety and Depression Scale, Toronto Alexithymia Scale-20 items and Structural Analysis of Social Behavior). Anthropometrics

Full Text available with Trip Pro

2017 BMC obesity

17. HbA1c point of care test for the diagnosis and management of diabetes mellitus

management Diabetes mellitus is a group of metabolic disorders characterised by hyperglycaemia resulting from defects in insulin secretion, action or both. Early detection and effective therapy providing good metabolic control, can delay the onset and progression of diabetes late complications, resulting in better outcomes for patients. The proposed medical service was for the use of in vitro diagnostic test instrument that meets defined acceptable performance criteria comparable to laboratory based (...) to have controlled diabetes compared with the pathology laboratory test over the 18 month trial period (65.5% vs 56.2%, [p<0.001]). Patients who received the HbA1c PoC test had lower hospital costs. The critique noted that evidence of the effectiveness of HBA1c PoC testing, related to the proportion of patients achieving good glycaemic control, was presented from two randomised controlled trials (RCT) (Khunti et al 2006; Laurence et al 2009). The Khunti et al (2006) trial had significant applicability

2017 Medical Services Advisory Committee

18. Treatment of Hypertension in Association With Diabetes Mellitus

even exceed those of aggressive glycemic control in people with diabetes mellitus for the prevention of cardiovascular complications . Because cardiovascular disease is the most common cause of death in patients with diabetes mellitus , BP control is paramount in these patients. In subjects with diabetes, there is randomized, clinical trial evidence supporting lower BP levels (two major trials are the United Kingdom Prospective Diabetes Study Group [UKPDS]-38 trial and the Hypertension Optimal (...) , ACCORD does not definitively answer the question of whether or not intensive blood pressure control in diabetes is beneficial. Neither the UKPDS-36 nor the HOT trials identified a threshold below which clinical benefit was no longer evident. The recommendation to lower SBPs to 130 mm Hg or less is partly based on prospective cohort data; specifically, the Pittsburgh Epidemiology of Diabetes Complications Study (in patients with type 1 diabetes mellitus) and the UKPDS-36 (in patients with type 2

2018 Hypertension Canada

19. Comment on Farren et al. The Prevention of Gestational Diabetes Mellitus With Antenatal Oral Inositol Supplementation: A Randomized Controlled Trial. Diabetes Care 2017;40:759-763. (PubMed)

Comment on Farren et al. The Prevention of Gestational Diabetes Mellitus With Antenatal Oral Inositol Supplementation: A Randomized Controlled Trial. Diabetes Care 2017;40:759-763. 29162587 2018 04 27 2018 12 02 1935-5548 40 12 2017 12 Diabetes care Diabetes Care Comment on Farren et al. The Prevention of Gestational Diabetes Mellitus With Antenatal Oral Inositol Supplementation: A Randomized Controlled Trial. Diabetes Care 2017;40:759-763. e172 10.2337/dc17-0847 Pintaudi Basilio B 0000-0002 (...) -5657-5183 Diabetes Unit, Niguarda Cà Granda Hospital, Milan, Italy basilio.pintaudi@ospedaleniguarda.it. Di Vieste Giacoma G Diabetes Unit, Cantù Hospital, Abbiategrasso, Italy. eng Letter Comment United States Diabetes Care 7805975 0149-5992 1406-16-2 Vitamin D 4L6452S749 Inositol IM Diabetes Care. 2017 Jun;40(6):759-763 28325784 Diabetes Care. 2017 Dec;40(12 ):e173 29162588 Diabetes Mellitus, Type 2 Diabetes, Gestational Female Humans Inositol Nutrition Therapy Pregnancy Vitamin D 2017 11 23 6 0

Full Text available with Trip Pro

2018 Diabetes Care

20. Response to Comment on Farren et al. The Prevention of Gestational Diabetes Mellitus With Antenatal Oral Inositol Supplementation: A Randomized Controlled Trial. Diabetes Care 2017;40:759-763. (PubMed)

Response to Comment on Farren et al. The Prevention of Gestational Diabetes Mellitus With Antenatal Oral Inositol Supplementation: A Randomized Controlled Trial. Diabetes Care 2017;40:759-763. 29162588 2018 04 27 2018 12 02 1935-5548 40 12 2017 12 Diabetes care Diabetes Care Response to Comment on Farren et al. The Prevention of Gestational Diabetes Mellitus With Antenatal Oral Inositol Supplementation: A Randomized Controlled Trial. Diabetes Care 2017;40:759-763. e173 10.2337/dci17-0024 Farren (...) Maria M Coombe Women & Infants University Hospital, Dublin, Ireland mariafarren1983@gmail.com. Turner Michael J MJ 0000-0002-9327-7652 Coombe Women & Infants University Hospital, Dublin, Ireland. Daly Sean S Coombe Women & Infants University Hospital, Dublin, Ireland. eng Letter Comment United States Diabetes Care 7805975 0149-5992 1406-16-2 Vitamin D 4L6452S749 Inositol IM Diabetes Care. 2017 Jun;40(6):759-763 28325784 Diabetes Care. 2017 Dec;40(12 ):e172 29162587 Diabetes Mellitus, Type 2 Diabetes

Full Text available with Trip Pro

2018 Diabetes Care

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>